Chimiothérapie des cancers épithéliaux de l’ovaire
| Autor: | Catherine Lhommé, Youssef Tazi, Alexandra Leary, Patricia Pautier |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Bevacizumab business.industry medicine.medical_treatment Obstetrics and Gynecology General Medicine Disease medicine.disease Carboplatin chemistry.chemical_compound Reproductive Medicine chemistry Paclitaxel Internal medicine medicine Ovarian carcinomas Ovarian cancer business Progressive disease medicine.drug |
| Zdroj: | Gynécologie Obstétrique & Fertilité. 41:611-616 |
| ISSN: | 1297-9589 |
| DOI: | 10.1016/j.gyobfe.2013.08.008 |
| Popis: | Chemotherapy is fundamental in the management of epithelial ovarian carcinomas both for early and advanced stages (rarely surgical treatment alone) and in almost every step of the disease. The reference schema combines carboplatin and paclitaxel intravenously. Intraperitoneal chemotherapy also proved its efficacy after complete surgery for advanced disease and should be reserved to trained teams due to its technical constraints and toxicity issues. Modalities of treatment in relapsed and progressive disease depend mainly on the free interval between this diagnosis and the last dose of platinum. Bevacizumab has proven its effectiveness in prolonging progression-free survival in 1st line setting in association with chemotherapy followed by maintenance and in case of relapse or progression both fore platinum sensitive or resistant disease. Finally, a better understanding of ovarian cancer biology will allow us to consider new molecular-targeted agents guided by the specific characteristics of each patient and each tumor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect